CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
3.320
+0.150 (4.73%)
At close: Aug 4, 2026, 4:00 PM EDT
3.374
+0.054 (1.62%)
Pre-market: Aug 5, 2026, 8:55 AM EDT

CytomX Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
35.5476.2138.1101.2153.1637.31
Revenue Growth
-75.91%-44.82%36.45%90.38%42.48%-45.47%
Gross Profit
35.5476.2138.1101.2153.1637.31
Operating Income
-64.66-22.3625-6.48-101.34-116.04
Net Income
-40.89-20.3731.87-0.57-99.32-115.87
Earnings Per Share
-0.41-0.150.38-0.01-1.51-1.81
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
346.71137.05100.62174.51193.65305.23
Total Debt
2.864.249.3913.9718.0618.06
Net Cash (Debt)
343.85132.8191.24160.54175.59287.17
Net Cash Growth
379.32%45.57%-43.17%-8.58%-38.85%-2.47%
Net Cash Per Share
2.150.961.082.182.674.48

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-80.09-75.59-86.23-56.04-110.79-119.03
Capital Expenditures
-0.1-0.22-0.31-0.84-1.74-1.61
Free Cash Flow
-80.19-75.81-86.54-56.88-112.53-120.64
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-181.92%-29.35%18.10%-6.41%-190.61%-311.00%
Pretax Margin
-165.74%-22.48%23.24%3.28%-186.82%-310.54%
Profit Margin
-115.05%-22.79%23.08%-0.56%-186.82%-310.54%
FCF Margin
-225.63%-99.48%-62.66%-56.19%-211.67%-323.33%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
--2.71---
Forward PE
-3.0347.9916.30--
PS Ratio
20.349.510.601.131.997.57